Pro-senescence therapy for hepatocellular carcinoma.
Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-University Munich, Germany.
Susanne
S
Muehlich
Thomas
T
Gudermann
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D016922:Cellular Senescence / Q000235:genetics / Q000502:physiology*; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D020690:GTPase-Activating Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D051379:Mice; D008954:Models, Biological; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D015398:Signal Transduction; D015534:Trans-Activators; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D025521:Tumor Suppressor Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology
C112352:DLC1 protein, human; D004268:DNA-Binding Proteins; D020690:GTPase-Activating Proteins; C431575:MRTFA protein, human; C478036:MRTFB protein, human; D015514:Oncogene Proteins, Fusion; D015534:Trans-Activators; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins